Literature DB >> 8940193

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.

R L Ilaria1, R A Van Etten.   

Abstract

The products of the Philadelphia chromosome translocation, P210 and P190(BCR/ABL), are cytoplasmic protein tyrosine kinases that share the ability to transform hematopoietic cytokine-dependent cell lines to cytokine independence but differ in the spectrum of leukemia induced in vivo. We have analyzed the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways in hematopoietic cells transformed by Bcr/Abl. STAT5 and, to a lesser extent, STATs 1 and 3 were constitutively activated by tyrosine phosphorylation and induction of DNA binding activity in both P210 and P190(BCR/ABL)-transformed cells, but P190 differed in that it also prominently activated STAT6. There was low level tyrosine phosphorylation of JAKs 1, 2, and 3 in Bcr/Abl-transformed cells, but no detectable complex formation with Bcr/Abl, and activation of STAT5 by P210 was not blocked by two different dominant-negative JAK mutants. These results suggest that P210 and P190(BCR/ABL) directly activate specific STAT family members and may help explain their overlapping yet distinct roles in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940193     DOI: 10.1074/jbc.271.49.31704

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  139 in total

1.  Enhanced hematopoietic differentiation of embryonic stem cells conditionally expressing Stat5.

Authors:  Michael Kyba; Rita C R Perlingeiro; Russell R Hoover; Chi-Wei Lu; Jonathan Pierce; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

2.  p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Afsar A Mian; Anna Metodieva; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

Review 4.  New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Jorge Cortes; Hagop Kantarjian
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

5.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

6.  The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B.

Authors:  Akiko Kimura; Cyril Martin; Gertraud W Robinson; James M Simone; Weiping Chen; Mark C Wickre; John J O'Shea; Lothar Hennighausen
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

7.  Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL.

Authors:  Gabriel J Sandoval; Daniel B Graham; Grzegorz B Gmyrek; Holly M Akilesh; Keiko Fujikawa; Benedicte Sammut; Deepta Bhattacharya; Shuba Srivatsan; Alfred Kim; Andrey S Shaw; Katherine Yang-Iott; Craig H Bassing; Eric Duncavage; Ramnik J Xavier; Wojciech Swat
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

8.  Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Authors:  L Schafranek; E Nievergall; J A Powell; D K Hiwase; T Leclercq; T P Hughes; D L White
Journal:  Leukemia       Date:  2014-05-12       Impact factor: 11.528

9.  Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Authors:  Iris Appelmann; Cory D Rillahan; Elisa de Stanchina; Gregory Carbonetti; Chong Chen; Scott W Lowe; Charles J Sherr
Journal:  Blood       Date:  2014-12-12       Impact factor: 22.113

Review 10.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.